Q3 EPS Estimates for Henry Schein Reduced by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC) – Equities research analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Henry Schein in a research report issued to clients and investors on Monday, August 24th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.33 for the quarter, down from their prior forecast of $1.38. The consensus estimate for Henry Schein’s current full-year earnings is $5.35 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2026 earnings at $1.40 EPS, FY2026 earnings at $5.32 EPS, Q1 2027 earnings at $1.38 EPS, Q2 2027 earnings at $1.39 EPS, FY2027 earnings at $5.82 EPS, Q1 2028 earnings at $1.57 EPS, Q2 2028 earnings at $1.56 EPS and FY2028 earnings at $6.32 EPS.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm had revenue of $3.46 billion for the quarter, compared to analysts’ expectations of $3.37 billion. During the same quarter last year, the business posted $1.10 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS.

Several other brokerages have also recently commented on HSIC. Robert W. Baird set a $97.00 price target on shares of Henry Schein in a research note on Wednesday, May 6th. Barrington Research set a $104.00 price objective on Henry Schein in a research report on Wednesday, August 5th. Citigroup reaffirmed a “buy” rating and issued a $112.00 target price (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. UBS Group set a $94.00 target price on Henry Schein and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, BMO Capital Markets assumed coverage on Henry Schein in a research note on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.93.

Henry Schein Stock Performance

HSIC opened at $89.51 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. The stock has a market capitalization of $9.98 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 1.69 and a beta of 0.80. The company has a fifty day moving average of $85.91 and a 200 day moving average of $79.66. Henry Schein has a fifty-two week low of $61.94 and a fifty-two week high of $92.18.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC boosted its stake in shares of Henry Schein by 47.3% during the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after purchasing an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after purchasing an additional 229 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Henry Schein in the 1st quarter worth about $676,000. Cetera Investment Advisers raised its position in Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after purchasing an additional 637 shares during the period. Finally, First Trust Advisors LP lifted its stake in Henry Schein by 0.8% in the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after purchasing an additional 1,669 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.